The FDA Approves Keytruda for primary Mediastinal Large B-Cell Lymphoma (PMBCL)
June 14, 2018
0
– Keytruda becomes the first anti-PD-1 therapy to be approved for PMBCL – This is the 2nd indication for Keytruda for a hematologic malignancy. – The approval is based on tumor response rate and durability of response. The FDA granted Merck (MRK) approval for its immuno-oncology checkpoint inhibitor Keytruda® for adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or for those who relapsed after two …